Shares of Natus Medical Incorporated (NASDAQ:NTUS) have been given an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.

Zacks has also given Natus Medical an industry rank of 145 out of 254 based on the ratings given to its competitors.

A number of equities analysts have recently issued reports on NTUS shares. TheStreet cut shares of Natus Medical from a “c-” rating to a “d+” rating in a research note on Friday, March 27th. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, June 16th. Finally, BidaskClub cut shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, June 19th.

A number of large investors have recently modified their holdings of the business. Cornercap Investment Counsel Inc. boosted its stake in Natus Medical by 1.0% during the 1st quarter. Cornercap Investment Counsel Inc. now owns 64,544 shares of the company’s stock worth $1,493,000 after acquiring an additional 664 shares during the last quarter. Swiss National Bank boosted its stake in Natus Medical by 1.4% during the 1st quarter. Swiss National Bank now owns 66,100 shares of the company’s stock worth $1,529,000 after acquiring an additional 900 shares during the last quarter. Altshuler Shaham Ltd bought a new position in Natus Medical during the 4th quarter worth approximately $33,000. Advisory Services Network LLC bought a new position in Natus Medical during the 4th quarter worth approximately $35,000. Finally, Hanson & Doremus Investment Management bought a new position in Natus Medical during the 1st quarter worth approximately $28,000. 89.21% of the stock is currently owned by hedge funds and other institutional investors.

Natus Medical stock traded down $0.29 during mid-day trading on Friday, reaching $20.55. The company had a trading volume of 712,826 shares, compared to its average volume of 345,542. The company has a quick ratio of 1.60, a current ratio of 2.13 and a debt-to-equity ratio of 0.19. Natus Medical has a 52 week low of $18.91 and a 52 week high of $34.89. The company has a 50 day moving average of $22.00 and a 200-day moving average of $26.92. The firm has a market cap of $694.63 million, a price-to-earnings ratio of 17.12 and a beta of 0.85.

Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.18). Natus Medical had a net margin of 2.51% and a return on equity of 9.91%. The company had revenue of $109.40 million during the quarter, compared to the consensus estimate of $115.00 million. Natus Medical’s revenue was down 4.9% on a year-over-year basis. On average, analysts predict that Natus Medical will post 0.5 earnings per share for the current fiscal year.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Recommended Story: Why are percentage gainers important?

Get a free copy of the Zacks research report on Natus Medical (NTUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.